Tumor infiltrating lymphocytes and methods of therapy

Patent metadata

Field	Value
Publication number	US-10912797-B2
Application number	US-201815947688-A
Country	US
Kind code	B2
Filing date	Apr 6, 2018
Priority date	Oct 18, 2016
Publication date	Feb 9, 2021
Grant date	Feb 9, 2021

Abstract

Genetically modified compositions, such as non-viral vectors and tumor infiltrating lymphocytes, for the treatment of gastrointestinal cancer are disclosed. Disclosed are methods of utilizing a CRISPR system to generate genetically modified compositions. Also disclosed are the methods of making and using the genetically modified compositions for the treatment of gastrointestinal cancer.

First claim

What is claimed is:

1. A method of treating cancer in a human subject in need thereof, comprising:
(a) administering a lymphodepleting preparative regimen that comprises an immunosuppressant in an amount sufficient to result in lymphodepletion in said human subject;
(b) administering a pharmaceutical composition that comprises an antifungal agent in an amount sufficient to inhibit a fungal infection in said human subject; and
(c) administering a pharmaceutical composition that comprises a plurality of tumor infiltrating lymphocytes (TILs), wherein said TILs comprise CD4+ T cells, wherein said CD4+ T cells comprise a genomic disruption of at least a portion of a cytokine inducible SH2-containing protein (CISH) gene, and wherein said genomic disruption suppresses or eliminates expression of a CISH protein encoded by said CISH gene thereby treating said cancer.

2. The method of claim 1 , further comprising administering a pharmaceutical composition that comprises an antibiotic in an amount sufficient to inhibit a bacterial infection in said human subject.

3. The method of claim 2 , wherein said antibiotic is cephalosporin, quinolone, penicillin, rifamycin, lipiarmycin, sulfonamide, macrolide, lincosamide, tetracycline, daptomycin, glycylcycline, tigecycline, oxazolidione, linezolid, lipiarmycins, fidaxomicin, cephazolin,cephalothin, cephapirin, cephalethin, cephradin, cephadroxin, amoxicillin, ampicillin, cefuroxime, cephamandole, cephoxitin, cephaclor, cephrozil, loracarbef, carbenicillin, ticarcillin, cephixime, cephtriaxone, cephotaxime, cephtizoxime, cephtazidime, cephipime, cephtaroline, cephtobiprole, trimethoprim, sulfamethoxazole, or pentamidine.

4. The method of claim 2 , wherein said pharmaceutical composition that comprises an antibiotic comprises trimethoprim, sulfamethoxazole, or both trimethoprim and sulfamethoxazole.

5. The method of claim 1 , wherein said immunosuppressant is cyclophosphamide, fludarabine, mechlorethamine, chlorambucil, melphalan, ifosfamide, thiotepa, hexamethylmelamine, busulfan, nitrosoureas, platinum, methotrexate, azathioprine, mercaptopurine, procarbazine, dacarbazine, temozolomide, carmustine, lomustine, streptozocin, fluorouracil, dactinomycin, anthracycline, mitomycin C, bleomycin, mithramycin, mycophenolate mofetil, rapamycin, cyclosporin, deoxyspergualin, soluble complement receptor 1, cobra venom factor, compstatin, methylprednisolone, leflunomide anti-thymocyte globulin antibody, anti-CD154 antibody, anti-CD40 antibody, anti-CD20 antibody, anti-IL-6R antibody, anti-IL-6 antibody, anti-IL-2R antibody, anti-CXCR3 antibody, anti-ICOS antibody, anti-OX40 antibody, or an anti-CD122 antibody, anti-C5 antibody, abatacept, belatacept, sirolimus, everolimus, tacrolimus, daclizumab, basiliximab, infliximab, eculizumab, rituximab, alemtuzumab, tocilizumab, sarilumab, or olokizumab.

6. The method of claim 1 , wherein said antifungal agent is an azole, polyene, allylamine, or echinocandin.

7. The method of claim 1 , further comprising administering a pharmaceutical composition that comprises an immunostimulant.

8. The method of claim 7 , wherein said immunostimulant is IL-2, IL-7, IL-12, IL-15, IL-21, or G-CSF, or any combination thereof.

9. The method of claim 7 , wherein said immunostimulant is aldesluekin.

10. The method of claim 1 , further comprising administering a pharmaceutical composition that comprises an infection prophylaxis agent.

11. The method of claim 10 , wherein said infection prophylaxis agent is a herpes virus prophylactic agent.

12. The method of claim 11 , wherein said herpes virus prophylactic agent is valacyclovir or acyclovir.

13. The method of claim 1 , wherein said immunosuppressant is cyclophosphamide.

14. The method of claim 13 , wherein said cyclophosphamide is administered to said subject at a dose from 50 mg per kg body weight of said subject to 80 mg per kg body weight of said subject.

15. The method of claim 1 , wherein said immunosuppressant is fludarabine.

16. The method of claim 15 , wherein said fludarabine is administered to said subject at a dose from 20 mg/m 2 to 30 mg/m 2 .

17. The method of claim 1 , wherein said preparative regimen comprises two immunosuppressants.

18. The method of claim 17 , wherein said two immunosuppressants are administered to said subject simultaneously or sequentially.

19. The method of claim 1 , wherein said antifungal is fluconazole, bifonazole, butoconazole, clotrimazole, econazole, fenticonazole, isoconazole, ketoconazole, luliconazole, miconazole, omoconazole, oxiconazole, sertaconazole, sulcoazole, tioconazole, albaconazole, efinaconazole, epoxiconazole, isavuvonazole, itraconazole, posaconazole, propiconazole, ravuconazole, terconazole, voriconazole, abafungin, amorolfin, butenafine, naftifine, terbinafine, anidulafungin, caspofungin, micafungin, aurones, benzoic acid, ciclopirox, flucytosine, griseofulvin, haloprogin, tolnaftate, undecylenic acid, cystal violet, or balsam of Peru.

20. The method of claim 19 , wherein said antifungal is fluconazole.

21. The method of claim 1 , wherein said cancer is gastrointestinal cancer, breast cancer, lymphoma, or prostate cancer.

22. The method of claim 1 , wherein said plurality of tumor infiltrating lymphocytes (TILs) are allogeneic to said human subject.

23. The method of claim 1 , wherein said plurality of tumor infiltrating lymphocytes (TILs) are autologous to said human subject.

24. The method of claim 1 , wherein said immunosuppressant is administered to said subject for 1 to 2 days, 1 to 3 days, 1 to 5 days, 3 to 5 days, 5 to 7 days, 7 to 10 days, 10 to 14 days, or 14 to 20 days.

25. The method of claim 1 , wherein said immunosuppressant is administered to said subject from 14 days to 24 hours, 10 days to 24 hours, or 7 days to 24 hours, before said administering of said pharmaceutical composition comprising said plurality of TILs to said subject.

26. The method of claim 1 , wherein said disruption is in exon 2 or exon 3 of said CISH gene.

27. The method of claim 1 , wherein said plurality of TILs further comprises CD8+ T cells that comprise said genomic disruption of said CISH gene, wherein said genomic disruption suppresses or eliminates expression of said CISH protein encoded by said CISH gene.

28. A method of treating cancer in a human subject in need thereof, comprising:
a) i) administering a pharmaceutical composition that comprises cyclophosphamide in an amount sufficient to reduce an immune response in said human subject and administering a pharmaceutical composition that comprises fludarabine in an amount sufficient to reduce an immune response in said human subject; or ii) administering a pharmaceutical composition that comprises cyclophosphamide and fludarabine in an amount sufficient to reduce an immune response in said human subject;
b) administering a pharmaceutical composition that comprises fluconazole in an amount sufficient to inhibit a fungal infection in said human subject; and
c) administering a pharmaceutical composition that comprises a plurality of tumor infiltrating lymphocytes (TILs), wherein said TILs comprise CD4+ T cells, wherein said CD4+ T cells comprise a genomic disruption of at least a portion of a cytokine inducible SH2-containing protein (CISH) gene, and wherein said genomic disruption suppresses or eliminates expression of a CISH protein encoded by said CISH gene, thereby treating

Assignees

• Univ Minnesota
• Intima Bioscience Inc
• Us Health
• The Us Secretary Department Of Health And Human Services Office Of Technology Transfer National Inst

Inventors

• Moriarity Branden
• Webber Beau
• Choudhry Modassir
• Rosenberg Steven A
• Palmer Douglas C
• Restifo Nicholas P

Classifications

• A61P31/10

  Antimycotics · CPC title

• A61K40/42

  Cancer antigens · CPC title

• A61K40/11

  T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title

• A61K2239/57

  Skin; melanoma · CPC title

• A61K2239/52

  Intestine · CPC title